Now loading.
Please wait.

Menu

director.niv@icmr.gov.in

Dr.Shyam Sundar Nandi

HomeDr.Shyam Sundar Nandi
HomeDr.Shyam Sundar Nandi
single image

Dr.Shyam Sundar Nandi

Designation: : Scientist E/ Deputy Director

Division: Biotechnology, ICMR-NIV Mumbai Unit

Educational qualifications: 1) M.Sc.-Biotechnology, 2)Ph.D.-Biotechnology, 3)Post Doc-Viral Genomics and Genome Editing Technologies (CRISPR Cas9), University of Illinois at Chicago, USA

Date of joining ICMR-NIV: :14th November 2008

  • Contact: :+91-9082553865 (Mobile), +91 22 24134130 (Extn 721)
  • Email: nandibiotech@gmail.com , drshyamnandi.icmr@gmail.com ,shyam.nandi@gov.in
  • Office: : ICMR-National Institute of Virology, Mumbai Unit, Haffkine Institute Compound, A.D. Marg, Parel, Mumbai-12

Research Interests:

    Major Specializations:
  • Biotechnology
  • Molecular Biology
    • Sub Specializations:
  • Molecular Virology
  • Genomics/ Genome Engineering
  • New Vaccine Development
  • CRISPR
  • CRISPR-based diagnostic (CRISPR-dx)
  • New Assay/Technology Development
  • Fields of specialization:
  • Application of Biotechnology to study Enteroviruses, Development of diagnostic assays, Application of CRISPR Cas9 technology to engineer cell strains, CRISPR-based diagnostic (CRISPR-dx), Enteroviruses and SARS-CoV-2

 

 

ORCID ID:0000-0002-0243-7199

Awards/Honours:

  • Awarded “ Best Technology Innovation Award” from Health Communication and Technology Summit, ICMR HQ, June 2023
  • Awarded “Dr. Kalyan Banerjee’s 85th Birth Anniversary Memorial Award 2023” for significant contribution to Science and Technology during 2018-2023.
  • “Award for Excellence in Science” for notable contribution in Genetic Engineering and Molecular Virology from Dr. Ananda Mohan Chakrabarti, Distinguished Scientist (1st Person on Earth who has received a patent on Live Organism (Oil Eating Bacteria), University of Illinois at Chicago, USA 2019
  • Awarded “Young Scientist Award” from Genomic and Technology Analysis International Conference, 2018 at Guwahati
  • Awarded “Appreciation Letter” from The Secretary DHR, DG-ICMR, 2019 for notable contribution to ICMR
  • Selected as a “Young Achiever in Science Award 2020-21” from Bencos Research Solutions.
  • Awarded “Start-up Grant” from Dept. of Health Research 2018
  • Awarded “Short-Term International Fellowship” for training in College of Medicine, University of Illinois at Chicago, USA from DHR 2017
  • Awarded “1st Prize for best innovation” from an International Conference (Bangalore India Bio2012, Bangalore).

Significant contributions to ICMR:

    Transfer of technologies
  • Rapid RT-LAMP kit for detection of SARS-CoV-2: It was easy, cost-effective rapid technology. This assay could enable field testing outside of the diagnostic laboratory like lower-level laboratories. During 2nd and 3rd wave, RT-LAMP kit has been extensively used to ramp up the national testing capacity in rural areas and Airports in India. The technology has been transferred to two companies (Acrannolife Genomics Pvt. Ltd, Chennai and Karwa Enterprises Pvt. Ltd-New Delhi). ICMR-NIV RT-LAMP kit has been extensively used for National testing in the name of COVIQWIK and COVI FAST. ICMR-NIV RT-LAMP kits are presently available in the name of COVIQWIK and COVIFast in India.
  • Silicosis Kit: The POC kit for early diagnosis of Silicosis/ Silico-TB will save many poor people’s lives and reduce the compensation amount from Govt. This work was carried out in collaboration with ICMR-NIOH and ICMR-NIV Mumbai Unit. The technology has been transferred to two companies (Axiva Sichem Biotech-Delhi, Acrannolife Genomics Pvt. Ltd, Chennai and). The silicosis kit will be available in the name of TRUESILICO (Acrannolife Genomics Pvt. Ltd, Chennai) and SilicoCheck (Axiva Sichem Biotech-Delhi). Technology has been transferred to 2 companies by ICMR HQ for manufacturing of the kits. The kits will be available in India in the name SilicoCheck and TRUSILICO soon. Early detection and necessary intervention could be a realistic possible control strategy for controlling silicosis as no effective treatment is available to stop and/or reverse the pathological process. Additionally, these patients are also vulnerable to pulmonary TB, which often becomes difficult to treat and with uncertain treatment outcome. Considering India’s huge burden of silicosis and silico-TB, it is important to early diagnose Silicosis and work towards TB prevention and screening among silica exposed. This assay would give an idea about an estimated lung injury caused by silica dust exposure before advising for their radiological confirmation to arrive at a confirmed diagnosis. ICMR-HQ is going to put the kit in the National Health Mission to control Silico-TB in India. This kit can be used periodically at regular intervals to assess all vulnerable unorganised sector/contractual workers with a history of silica dust exposure and to be linked with Aadhar Number in India to save their lives.
  • Polio non-permissive cell line (CD155/PVR RD knockout cells): It is clear from WHO GAP III/IV that laboratories wanting to culture viruses from poliovirus potentially infectious materials like human faecal samples, human throat secretions and environmental waters in poliovirus permissive cell lines will have to establish bio-safety and bio-risk management systems and obtain verification/ certification by National Containment Authority. This may prove very expensive for the laboratories. A poliovirus non-permissive cell line supporting growth of Non polio Enteroviruses would be a boon to these researchers. Thus, poliovirus non-permissive cell line will be beneficial to the Researcher who are working on Non polio enteroviruses. The CD155/PVR knockout RD cells will find wide applications in laboratories worldwide.The CD155/PVR knockout cells RD can be used safely in all non-polio laboratories wanting to grow non-polio enteroviruses from clinical samples (stool or respiratory secretions) for diagnostic purposes and research without the fear of poliovirus growth as inadvertent contamination.Deposited newly “developed RD-Knockout polio non-permissive cell line” using CRISPR Cas9 to ATCC, USA. We have successfully submitted the cell line to ATCC, USA after taking all permission from the Director, NIV, DG-ICMR, RCGM Dept. of Biotechnology, Govt. of India. A MoU will be signed soon between ATCC, USA and DG, ICMR for commercialization of the newly developed cell line. After publication in Journal of Medical Virology (IF 20.69). I was invited by WHO HQ for a presentation in 29th Informal Consultation of the Global Polio Laboratory Network (GPLN), WHO, 14-15 December 2022, Geneva, Switzerland. It was discussed that the WHO Global Polio Laboratory Network will also support use of CD155 knockout RD cells for Enterovirus work in the 146 network laboratories all over the World.
  • Polio non-permissive cell line (CD155/PVR HEK293 knockout cells): We have successfully developed CD155/PVR HEK293 knockout cells using CRISPR Cas9. Thus, poliovirus non-permissive cell line will be beneficial to the Researcher who are working on enteric viruses. The CD155/PVR knockout HEK293 cells will find wide applications in laboratories worldwide. The CD155/PVR knockout cells HEK293 can be used safely in all non-polio laboratories wanting to grow enteric viruses from clinical samples (stool or respiratory secretions) for diagnostic purposes and research without the fear of poliovirus growth as inadvertent contamination.
  • LAMP Kit for Diphtheria:Diphtheria is an acute, highly infectious, and potentially lethal disease caused by diphtheria toxin-producing bacterial strains of C. diphtheriae. Successfully RT-LAMP assay for Corynebacterium diphtheriae has been developed. IPR has been submitted via ICMR HQ. International PCT application has also been submitted via IPR cell, ICMR HQ. RT-LAMP assay is ready for commercialization for detection of Corynebacterium diphtheriae. This work was carried out in collaboration with ICMR-NIE and ICMR-NIV Mumbai Unit. The kit can be used for screening and diagnosis of Diphtheria and can differentiate between toxigenic and non-toxigenic diphtheria. This technology can be implemented in lower-level laboratories where sophisticated machines are unavailable. This assay could enable point-of-care testing outside of the diagnostic laboratory and can be applied for contact tracing and diagnosis in field conditions. It is cost effective and less time-consuming technology. Technology will be transferred to suitable manufacturers soon.
  • Development of a colorimetric isothermal assay for detection of Monkeypoxvirus: This assay can be used for diagnosis of Monkeypox, where quantitative detection is not necessary. The assay will be most preferred for detection of Monkeypox virus and differentiating it from the other members of Orthopoxvirus genus. The assay specifically detects two genes of Monkeypox virus (genus specific B6R gene and species specific F3L gene). The Results can be interpreted visually; no other sophisticated instruments are required for interpretation of results. This assay could enable point-of-care testing outside of the diagnostic laboratory. Technology will be transferred to suitable manufacturers soon.
  • Development of a colorimetric isothermal (RT-LAMP) assay for rapid detection of Nipah virus: For Nipah virus infection, there is no vaccine or other medical antiviral treatment available and the mortality rate is around 60-90%. Hence, the development of a rapid molecular is of prime importance because there are no effective field tests available currently for the detection of Nipah virus. It is an indigenous RT-LAMP based assay for the detection of Nipah virus. The assay can be performed using a single temperature heating device (62 ± 1O C) and the time required for the assay is only 40 minutes. The results can be interpreted visually; no other sophisticated instruments are required for interpretation of results. This assay could enable point-of-care testing outside of the diagnostic laboratory. Technology will be transferred to suitable manufacturers soon.
  • Vaccine development against Enterovirus A71: We have been working for the last 3 years to develop a vaccine against Enterovirus A71 using CRISPR Cas. We are trying to increase the titre of EV A71 using CRISPR. We have found very satisfactory results till now.


  • List of Patents (Indian & Overseas) filed & granted:
    • Sr. No. Title of the Patent Inventors (Lead Person name in bold letters) Indian patent application Number with month and year International patent Number with month and year Patent Number with country in which it is patented (if granted)
    1 An Assay for detection of Nucleotide Substitutions in Genome of Sabin Oral Poliovirus Vaccine Viruses Shyam Sundar Nandi (PI), Jagadish Mohan Deshpande, Deepa Kailash Sharma Indian patent: Patent Application no.: 526/DEL/2010 International patent: PCT Application no.: PCT/IN2012/000160, March 2012. Entered in national phase filing in China, Hong kong and Brazil.
    a) Chinese Patent Application No.: 201280023280.7, March 2012
    b) Brazilian Patent Application No: 2013030390.5, March 2012 c) Hong kong Patent Application No. HK14107809.0A    		 Granted Indian Patent No 288790, October 2017, Granted Chinese Patent No.:ZL201280023280.7, March 2016, Granted Hong Kong Patent No.:HK 1194438 February 2018
    2 An assay to detect human gene CD155 polymorphism at nucleotide number 199 in Exon2 Shyam Sundar Nandi (PI), Jagadish Mohan Deshpande Indian patent applications: Patent application no.: 2033/DEL/2013 International patent applications: PCT Application no.: PCT/IN2014/000456. Granted Indian Patent Number :405698. As per Indian Patent Office website, Grant date is 05/09/2022
    3 Development of a colorimetric isothermal assay for detection of Monkeypox virus Shyam Sundar Nandi (PI), Upendra Lambe, Sonali Sawant, Yadav Pragya, Shete-Aich Anita, Jagadish Deshpande Indian Patent Application No: 202211057074, October 2022  
    4 Development of a colorimetric isothermal (RT-LAMP) assay for rapid detection of Nipah virus Shyam Sundar Nandi (PI), Upendra Lambe, Sonali Sawant, Yadav Pragya, Shete-Aich Anita, Jagadish Deshpande Indian Patent Application No: 202211066352, November 2022
    5 Development of genetically tailored organotypic model of human intestine for study of enteroviruses Alpana Moghe, Shyam Sundar Nandi, Sara Kamyab, Upendra Lambe, Sonali Sawant, Sakshi Phalke, Dr. Chiranjib Chakraborty, Dr. Ramesh Bhonde Indian Patent Application No: 202311003845, January 2023
    6 Development of HEK293 knock-out cell line of EV-A71 receptors SCARB2 and PSGL1 genes Shyam Sundar Nandi (PI), Upendra Lambe, Ms. Sonali Sawant, Jagadish Deshpande. Indian Patent Application No: 202111048030, September 2021. Present status as per Indian Patent Office: Patent application is published in April, 2023 and awaiting examination by Patent Office.
    7 Instrument free nucleic acid extraction method Shyam Sundar Nandi (PI), Upendra Lambe, Ms. Sonali Sawant, Jagadish Deshpande Indian Patent Application No: 202111043228, August 2021. Present status as per Indian Patent Office: Patent application is published in March, 2023 and awaiting examination by Patent Office.
    8 Development of screening assays for detection of epidemiologically important SARS-CoV-2 variants Shyam Sundar Nandi (PI), Upendra Lambe, Ms. Sonali Sawant, Jagadish Deshpande Indian Patent Application No: 202111032470, July 2021. Present status: Indian Patent application is published in March, 2023 and awaiting examination by Patent Office. PCT application no. (PCT/IN2022/050649) is filed in 19.07.2022 and published by WIPO in Jan. 2023. Publication of WO2023002505A1
    9 Development of a colorimetric isothermal assay for detection of Corynebacterium diphtheria Shyam Sundar Nandi (PI), Subarna Roy, Upendra Lambe, Sonali Sawant, Trupti Gohil, Monoj Murekar, Jagadish Deshpande Indian Patent Application Number 202111015391, Macrh 2021),Present Status: Indian Patent application is published in February 2023, Request for Examination filed and now awaiting examination by Patent Office. International PCT application no.PCT/IN2022/050276 is filed in March 2022 and Published by WIPO in October 2022
    10 Rapid RT-LAMP assay for detection of SARS-CoV-2 Shyam Sundar Nandi (PI), Upendra Lambe, Sonali Ankush Sawant, Trupti Gohil, Dr. Jagadish Deshpande Indian Patent Application Number: 202011023573, June 2020, Present Status: Indian Patent application is published in Dec., 2021, Request for Examination filed and now awaiting examination by Patent Office. International PCT application no. (PCT/IN2021/050549) is filed in 05.06.2021 and published by WIPO in Dec., 2021. National phase corresponding to PCT application is filed in Italy (Patent Application No. 112022000176184 filed on 05/12/2022) and Brazil (Patent Application No.BR 11 20220247109 filed on 02/12/2022).
    11 RT-LAMP Assay for detection of human β -Actin housekeeping gene Shyam Sundar Nandi (PI), Upendra Lambe, Sonali Ankush Sawant, Trupti Gohil, Dr. Jagadish Deshpande Indian Patent Application Number: 202111012867, March2021. Present status: Indian Patent application is published in December, 2022, Request for Examination filed and now awaiting examination by Patent Office. International PCT Application No. PCT/IN2022/050183 is filed in 03.03.2022 and Published by WIPO in September 2022
    12 A Point of Care Device, Method and Kit involving Club Cell protein 16 as a marker for Silicosis Shyam Sundar Nandi (PI), Upendra Lambe, Kamalesh Sarkar, Sonali Sawant, Jagadish Deshpande Indian Patent Application No: 202011014266, March,2020. Present Status: Indian Patent application is published in Sept., 2022, filing of request for examination is under process International PCT application No. PCT/IN2021/050328 dated 31st March 2021.National phase corresponding to PCT application is filed in following countries:
    USA patent application no.: US 17/904,201 filed on 12.08.2022
    Brazilian patent application no.: BR 11 2022 018935-4 filed on 21.09.2022
    South African patent application no. 2022/08022 filed on19 July 2022
    European patent application no.: EP 21781546.3 filed on 25.07.2022    		  
    13 Poliovirus receptor (PVR/CD155) knockout cells derived from RD (human rhabdomyosarcoma) cell line by CRISPR Shyam Sundar Nandi (PI), Sonali Sawant, Jagadish Deshpande Indian Patent Application No: 201811034727, September 2018.Present status: Indian Patent Application filed on 14/09/2018 and is now under examination by Indian Patent office. 2nd Information Reply Filed January 2023. Application in amended examination International PCT No. PCT/IN2019/050671 filed on 13th Sept. 2019. National phase corresponding to PCT application is filed in following countries:
    European Patent Application: EP 19859775.9 filed on 15-Mar-2021
    USA Patent Application No.17/275,991 filed on 12-Mar-2021
    14 Assay to investigate multiple genes as host genetic risk factors for Enterovirus71 infection severity Shyam Sundar Nandi (PI), Sonali Sawant, Jagadish Deshpande Indian patent application no: 201811023228. Present status as per IPO: Reply Filed. Application in amended examination International PCT Application Number PCT/IN2019/050468.  
List of Publications

  • 1.Nandi SS*, Sawant SA, Gohil T, Sangal L, Patel D, Krishnasamy K, Ghoshal U, Harvey P, Deshpande JM. Poliovirus non-permissive CD155 knockout cells derived from RD cell line using CRISPR technology for handling poliovirus potentially infectious materials in virology laboratories. J. Med. Virol. 2022; 1–9. DOI: 10.1002/jmv.27897 (Impact factor 20.69)

  • 2. Nandi SS*, Lambe UP, Sarkar K, Sawant S, Deshpande J. A rapid point of care CC16 kit for screening of occupational silica dust exposed workers for early detection of silicosis/silico- tuberculosis. Nature Scientific Reports. 2021 Dec 6;11(1):1-8. DOI: 10.1038/s41598-021- 02392-y. (Impact factor 5.516)

    3. Nandi SS*, Lambe UP, Sawant SA, Gohil T, Deshpande J. Development of a RT-LAMP assay for detection of SARS-CoV-2. Ind. J. Med. Res. 2022. DOI: 10.4103/ijmr.IJMR_713_21 (Impact factor 5.274)

    4.Nandi SS*, Bhattacharya I, Lambe U, Sawant S, Gohil T, Yadavalli T, Shukla D. Ophthalmic Manifestations of COVID-19 and its Association with Heparan Sulfate Receptors. TOOAJ 3(3) 271-283. DOI: 10.32474/TOOAJ.2021.03.000161. (Impact factor 3.1)

    5. Manisha Dhanshetty, Supriya Kusale, Vijayshree Chavan, Shraddha Shewale, Upendra P. Lambe, Sonali A. Sawant, Shyam Sundar Nandi, Sujoy Saha, Somnath Holkar, Jagruti Jankar, Ramhari Somkuwar and Kaushik Banerjee. Rapid monitoring of SARS-CoV-2 on fruits and vegetables using reverse-transcription loop-mediated isothermal amplification assay. Current Science 2022, Vol. 124, No. 8; 938-945. Impact Factor 1.169

    6. Pal D, Raj K, Nandi SS, Sinha S, Mishra A, Mondal A, Lagoa R, Burcher JT, Bishayee A. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies. Cancers. 2023; 15(10):2808. https://doi.org/10.3390/cancers15102808. (Impact Factor 5.2)

    7. Nandi SS*, Gohil T, Sawant SA, Lambe UP, Ghosh S, Jana S. CD155: A Key Receptor Playing Diversified Roles. Curr. mol. med. 2022. 22 (7) 594 – 607. DOI: 10.2174/1566524021666210910112906. (Impact factor 2.222)

    8. Bellamkonda N, Lambe UP, Sawant S, Nandi SS*, Chakraborty, C.; Shukla, D. Immune Response to SARS-CoV-2 Vaccines. Biomedicines 2022, 10, 1464. DOI: org/10.3390/biomedicines10071464. (Impact factor 6)

    9. Chakraborty C, Bhattacharya M, Nandi SS, Mohapatra RK, Dhama K, Agoramoorthy G. Appearance and re-appearance of zoonotic disease during the pandemic period: long-term monitoring and analysis of zoonosis is crucial to confirm the animal origin of SARS-CoV-2 and monkeypox virus. Vet Q. 2022, 7;42(1):119-124. DOI: 10.1080/01652176.2022.2086718 (Impact factor 3.32)

    10. Chakraborty C, Sharma AR, Bhattacharya M, Mallik B, Nandi SS*, Lee SS. Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. Infect Genet Evol. 2022;101:105282. DOI: 10.1016/j.meegid.2022.105282. (Impact factor 3.342

    11. Chakraborty C, Bhattacharya M, Sharma AR, Roy SS, Islam MA, Chakraborty S, Nandi SS*, Dhama K. Deep learning research should be encouraged for diagnosis and treatment of antibiotic resistance of microbial infections in treatment associated emergencies in hospitals. International Journal of Surgery. 2022, 24:106857. DOI: 10.1016/j.ijsu.2022.106857 (Impact factor 13.4)

    12. Wu D, Koganti R, Lambe UP, Yadavalli T, Nandi SS*, Shukla D. Vaccines and Therapies in Development for SARS-CoV-2 Infections. J Clin Med. 2020 Jun 16; 9(6):1885. PMID: 32560227; PMCID: PMC355822. DOI: 10.3390/jcm9061885 (Impact factor: 4.566)

    13. Kumar N, Tripathi N, Kanchibotla D, Kumari M, Nandi SS* Virucidal Effect of Medicinal Smoke for Mass Fumigation using Hawan Techniques during SARS-CoV-2 Pandemic: A Review. J Adv Res Med Sci Tech 2020; 7(2): 1-7. DOI: 10.24321/2394.6539.202009 (Impact factor: 0.86)

    14. Nandi S, Shrama D, Deshpande J. Assay for identification of heterozygous single-nucleotide polymorphism (Ala67Thr) in human poliovirus receptor gene. Indian J Med Res 2016: 144:38-45 DOI: 10.4103/0971-5916.193281 (Impact factor 5.274)

    15. Chakraborty C, Nandi S, Sarkar B and Sinha S. (2005). Over-expression and purification of recombinant eel calcitonin and its phylogenetic analysis. Protein and Peptide Letters. 12: 263-269. DOI: 10.2174/0929866053587147 (Impact factor: 1.87)

    16. Chakraborty C, Jana S and Nandi SS* (2005). Prion disease: a deadly disease for protein misfolding. CurrPharmBiotechnol.6:167-177.DOI: 10.2174/1389201053642321 (Impact factor: 2.837)

    17. Chakraborty C, Nandi S and Sinha S. (2004). Over expression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in Streptomyces avermitilis. Protein and Peptide Letters. 11: 165-173. DOI: 10.2174/0929866043478266 (Impact factor: 1.87)

    18. Jana S, Chakraborty C, Nandi S (2004). RNA interface: potential therapeutic targets. Applied Microbiology and Biotechnology. 65: 649-657. DOI: 10.1007/s00253-004-1732-1 (Impact factor: 4.813)

  • Book chapters:

    1. Nandi SS*, Paul P, Lambe UP, Phalke S, Sawant SA, Moghe A, Ghosh S, Kumar N, Chakraborty C. Herbal drugs against polio infections: ethnopharmacology, chemistry, clinical and preclinical studies, Book entitled “Anti-Viral Metabolites from Medicinal Plants”, from SPRINGER NATURE (Accepted).

    2. Nandi SS*, Phalke S, Paul P, Sawant SA, Lambe UP, Bellamkonda N and Shukla D. Medicinal plants against Herpes Simplex Virus Type–1 Infections: Ethnopharmacology, Chemistry, clinical and preclinical studies, Book entitled “Anti-Viral Metabolites from Medicinal Plants”, from SPRINGER NATURE (Accepted).

    3. Moghe A, Deshpande M, Kamyab S, Chunarkar PP, Nandi SS*, Bhatt, N. Hepatitis C (HCV) and the role of phytochemicals in the antiviral effects of different medicinal plants against infection, Book entitled “Anti-Viral Metabolites from Medicinal Plants”, from SPRINGER NATURE (Accepted).

    4. S Phalke, S A Sawant, P Yadav, C Chakraborty, A Jadhav, SS Nandi* Viral genome sequencing and its significance in latest clinical and research findings”, Book entitled” Microbial diversity in the genomic era: Functional diversity and community analysis, Second Edition, from Elsevier (Submitted), 2023

    5. Nandi S*, Chakraborty C, Gothalwal R (2004). Human Granulocyte-Colony Stimulating Factor: A Therapeutic Protein. Advances in Biochemistry and Biotechnology. Volume-1, Daya Publishing House. 4762-63/23, Ansari Road Darya Gang, New Delhi-110002

    6. Sinha S, Nandi S, Chakraborty C, Jana S, Verma A, Gothalwal R and Maiti TK. (2004). Protein Folding Pathways - Its Kinetics and Related Functions. Advances in Biochemistry and Biotechnology. Volume-1, Daya Publishing House. 4762-63/23, Ansari Road Darya Gang, New Delhi-110002

All for Joomla All for Webmasters